Quick Answer
Acrivon Therapeutics, Inc. reported Total Assets of $129.72 million for the year ending 2025.
- Acrivon Therapeutics, Inc. showed a decrease of -34.0% in Total Assets from 2024 to 2025.
- This data is from Acrivon Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $87.71 million | Q1 2023: $170.20 million | Q2 2023: $160.05 million | Q3 2023: $151.09 million | Q1 2024: $120.52 million | Q2 2024: $230.59 million | Q3 2024: $214.68 million | Q1 2025: $176.35 million | Q2 2025: $158.58 million | Q3 2025: $145.30 million.
- Over the full 5 years of available data (2021 to 2025), Acrivon Therapeutics, Inc.'s Total Assets has grown by 21.7%.
- Historical annual values: Fiscal year 2025: $129.72 million | Fiscal year 2024: $196.59 million | Fiscal year 2023: $138.27 million | Fiscal year 2022: $181.23 million | Fiscal year 2021: $106.59 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: